Others have shown that myeloma is driven by mutations in the RAS signaling pathway, and that KRAS/NRAS mutations are present in 20%–50% and 45%–80% of newly diagnosed and relapsed/refractory myeloma cases, respectively.9, 11, 12, 13. Here, KRAS is linked to plasma cell myeloma.